B-cell maturation agent (BCMA) is a very popular target for Multiple Myeloma therapies currently in development. Gareth Morgan, MD, FRCP, FRCPath, PhD of NYU Langone joins the Myeloma Crowd at ASH to review the BCMA-targeting therapies being reviewed at the meeting.   There are three key immunotherapy approaches that all look highly effective for the [...]